Verrica amends credit agreement, waives going concern covenant through Dec 2025

Verrica Pharmaceuticals Inc.

Sixth amendment waives Section 7.1(b) and 7.1(c) going concern qualifications for Q2'25, Q3'25, and FY2025 financial statements.
Company paid amendment fee of $110,465.12 to lenders (OrbiMed Royalty & Credit Opportunities IV, LP).
Original credit agreement dated July 26, 2023; all other terms unchanged.
Waiver addresses potential default risk from going concern audit language in upcoming filings.

item 1.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.